MA35351B1 - Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète. - Google Patents
Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète.Info
- Publication number
- MA35351B1 MA35351B1 MA36755A MA36755A MA35351B1 MA 35351 B1 MA35351 B1 MA 35351B1 MA 36755 A MA36755 A MA 36755A MA 36755 A MA36755 A MA 36755A MA 35351 B1 MA35351 B1 MA 35351B1
- Authority
- MA
- Morocco
- Prior art keywords
- diabetes
- novel
- treatment
- derivative useful
- tetrahydroquinoline derivative
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical class C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161524462P | 2011-08-17 | 2011-08-17 | |
| PCT/US2012/050051 WO2013025424A1 (en) | 2011-08-17 | 2012-08-09 | A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35351B1 true MA35351B1 (fr) | 2014-08-01 |
Family
ID=46690732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36755A MA35351B1 (fr) | 2011-08-17 | 2014-02-13 | Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8431706B2 (enExample) |
| EP (1) | EP2744806B1 (enExample) |
| JP (1) | JP5903162B2 (enExample) |
| KR (1) | KR101570624B1 (enExample) |
| CN (1) | CN103687856B (enExample) |
| AP (1) | AP3589A (enExample) |
| AR (1) | AR087451A1 (enExample) |
| AU (1) | AU2012295372A1 (enExample) |
| BR (1) | BR112014003079A2 (enExample) |
| CA (1) | CA2843474C (enExample) |
| CL (1) | CL2014000357A1 (enExample) |
| CO (1) | CO6880069A2 (enExample) |
| CR (1) | CR20140052A (enExample) |
| DO (1) | DOP2014000018A (enExample) |
| EA (1) | EA022165B1 (enExample) |
| EC (1) | ECSP14013211A (enExample) |
| ES (1) | ES2578165T3 (enExample) |
| GT (1) | GT201400022A (enExample) |
| IL (1) | IL230635A (enExample) |
| IN (1) | IN2014MN00191A (enExample) |
| MA (1) | MA35351B1 (enExample) |
| MX (1) | MX2014001832A (enExample) |
| PE (1) | PE20140831A1 (enExample) |
| PH (1) | PH12014500366A1 (enExample) |
| SG (1) | SG11201401793PA (enExample) |
| TN (1) | TN2014000058A1 (enExample) |
| TW (1) | TWI537262B (enExample) |
| UA (1) | UA110983C2 (enExample) |
| WO (1) | WO2013025424A1 (enExample) |
| ZA (1) | ZA201400705B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2928097A1 (en) | 2013-11-14 | 2015-07-02 | Cadila Healthcare Limited | Novel heterocyclic compounds |
| EP3076959B1 (en) | 2013-12-04 | 2018-07-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2015119899A1 (en) | 2014-02-06 | 2015-08-13 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| CN109666027A (zh) * | 2017-10-17 | 2019-04-23 | 中国科学院上海药物研究所 | 一类酰胺结构的gpr40激动剂化合物及其用途 |
| DK3737470T5 (da) | 2018-01-08 | 2024-05-27 | Celon Pharma Sa | 3-phenyl-4-hexynsyrederivater som gpr40-agonister |
| SI3752501T1 (sl) | 2018-02-13 | 2023-08-31 | Gilead Sciences, Inc. | Inhibitorji pd-1/pd-l1 |
| CA3093130C (en) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| SI3820572T1 (sl) | 2018-07-13 | 2023-12-29 | Gilead Sciences, Inc. | Inhibitorji pd-1/pd-l1 |
| JP7158577B2 (ja) | 2018-10-24 | 2022-10-21 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| US20220213051A1 (en) * | 2019-05-31 | 2022-07-07 | Hyundai Pharm Co., Ltd. | Novel crystal form of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative |
| TWI751585B (zh) * | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| WO2021083270A1 (zh) * | 2019-10-31 | 2021-05-06 | 中国石油化工股份有限公司 | 负载型催化剂及其制备方法和应用 |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| AU2021275038A1 (en) | 2020-05-19 | 2022-12-22 | Kallyope, Inc. | AMPK activators |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| KR102699076B1 (ko) * | 2021-04-01 | 2024-08-27 | 현대약품 주식회사 | 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도 |
| CN115317484B (zh) * | 2022-08-26 | 2023-07-18 | 北京箭牧科技有限公司 | Ly2922470在制备预防或治疗脑血管疾病或组织缺血再灌注损伤药物中的应用 |
| CN115671105B (zh) * | 2022-11-22 | 2023-10-27 | 北京箭牧科技有限公司 | Ly2922470在制备预防或治疗肾脏疾病药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| IL157093A0 (en) * | 2001-03-27 | 2004-02-08 | Actelion Pharmaceuticals Ltd | 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists |
| US7816367B2 (en) | 2004-02-27 | 2010-10-19 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| JP4875978B2 (ja) * | 2004-03-15 | 2012-02-15 | 武田薬品工業株式会社 | アミノフェニルプロパン酸誘導体 |
| US7517910B2 (en) * | 2004-03-30 | 2009-04-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| AR078522A1 (es) * | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
| AR078948A1 (es) | 2009-11-30 | 2011-12-14 | Lilly Co Eli | Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes |
-
2012
- 2012-08-03 AR ARP120102845A patent/AR087451A1/es unknown
- 2012-08-03 TW TW101128102A patent/TWI537262B/zh not_active IP Right Cessation
- 2012-08-09 PH PH1/2014/500366A patent/PH12014500366A1/en unknown
- 2012-08-09 CA CA2843474A patent/CA2843474C/en not_active Expired - Fee Related
- 2012-08-09 ES ES12748334.5T patent/ES2578165T3/es active Active
- 2012-08-09 KR KR1020147003634A patent/KR101570624B1/ko not_active Expired - Fee Related
- 2012-08-09 US US13/570,342 patent/US8431706B2/en not_active Expired - Fee Related
- 2012-08-09 SG SG11201401793PA patent/SG11201401793PA/en unknown
- 2012-08-09 MX MX2014001832A patent/MX2014001832A/es unknown
- 2012-08-09 JP JP2014526078A patent/JP5903162B2/ja not_active Expired - Fee Related
- 2012-08-09 EA EA201490269A patent/EA022165B1/ru not_active IP Right Cessation
- 2012-08-09 EP EP12748334.5A patent/EP2744806B1/en active Active
- 2012-08-09 PE PE2014000218A patent/PE20140831A1/es not_active Application Discontinuation
- 2012-08-09 AP AP2014007436A patent/AP3589A/xx active
- 2012-08-09 CN CN201280036072.0A patent/CN103687856B/zh not_active Expired - Fee Related
- 2012-08-09 UA UAA201401073A patent/UA110983C2/uk unknown
- 2012-08-09 BR BR112014003079A patent/BR112014003079A2/pt not_active IP Right Cessation
- 2012-08-09 WO PCT/US2012/050051 patent/WO2013025424A1/en not_active Ceased
- 2012-08-09 AU AU2012295372A patent/AU2012295372A1/en not_active Abandoned
-
2013
- 2013-01-30 CR CR20140052A patent/CR20140052A/es unknown
-
2014
- 2014-01-23 IL IL230635A patent/IL230635A/en not_active IP Right Cessation
- 2014-01-28 DO DO2014000018A patent/DOP2014000018A/es unknown
- 2014-01-29 ZA ZA2014/00705A patent/ZA201400705B/en unknown
- 2014-01-30 IN IN191MUN2014 patent/IN2014MN00191A/en unknown
- 2014-02-10 TN TNP2014000058A patent/TN2014000058A1/en unknown
- 2014-02-13 GT GT201400022A patent/GT201400022A/es unknown
- 2014-02-13 CL CL2014000357A patent/CL2014000357A1/es unknown
- 2014-02-13 MA MA36755A patent/MA35351B1/fr unknown
- 2014-02-14 CO CO14032116A patent/CO6880069A2/es active IP Right Grant
- 2014-02-17 EC ECSP14013211 patent/ECSP14013211A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35351B1 (fr) | Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète. | |
| MA33840B1 (fr) | Nouveau composé de spiropipéridine | |
| MA35432B1 (fr) | Composé pour le traitement et la prophylaxie de la maladie du virus respiratoire syncytial | |
| JOP20210064A1 (ar) | عملية لتحضير 5- فلورو-1h- بيرازولوبيريدينات مستبدلة | |
| EA201491012A1 (ru) | Гетероциклические ингибиторы глютаминазы | |
| MA35128B1 (fr) | Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite | |
| MA33662B1 (fr) | Composés de spiropipéridine et leur utilisation pharmaceutique pour le traitement du diabète | |
| EA201301019A1 (ru) | Бензодиоксановые ингибиторы продуцирования лейкотриена | |
| MA34965B1 (fr) | Procédé de production de dérivé de dihydrobenzofurane optiquement actif | |
| MA44721A (fr) | Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer | |
| MA35623B1 (fr) | Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives | |
| IN2014MN02106A (enExample) | ||
| MA38227A1 (fr) | Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase | |
| MA37888B1 (fr) | Composition pharmaceutique enrobée contenant du régorafenib | |
| EA201491824A1 (ru) | Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1 | |
| EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
| MA38333A1 (fr) | Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| MA37405A1 (fr) | Composés hétérocyclyle | |
| MA40895B1 (fr) | Synthèse de copanlisib et son sel de dichlorhydrate | |
| EA201491747A1 (ru) | Замещенные пиридопиримидиновые соединения и их применение в качестве flt3 ингибиторов | |
| MA35016B1 (fr) | Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt | |
| JOP20130213B1 (ar) | معارضات لمستقبلht3-5 | |
| MA39048B1 (fr) | Nouveaux inhibiteurs de la dgat2 | |
| TN2012000620A1 (fr) | Procede de preparation du sel de l-arginine du perindopril |